aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
NeuroPace, founded in Mountain View, California, focuses on designing, developing, and marketing implantable devices to treat neurological disorders through responsive stimulation. Their core mission is to improve the quality of life for patients with epilepsy by offering innovative, technology-driven solutions. The company's flagship product, the RNS System, provides personalized treatment by monitoring brain activity and delivering precise electrical stimulation to prevent seizures. NeuroPace targets both patients and healthcare providers, aiming to revolutionize epilepsy management.
Notable figures associated with NeuroPace include key investors from prominent venture capital firms and experts in neurology and medical device innovation. The company has achieved significant milestones, including FDA approval for the RNS System and widespread adoption in clinical settings. NeuroPace's impact is evident in the improved outcomes for epilepsy patients, reducing seizure frequency and enhancing overall patient well-being. Their pioneering work in responsive neurostimulation has positioned them as leaders in the field of neurological disorder treatment.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Medical Devices
Technology
AI
Tags
Biotech
Model Types
Hardware
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was NeuroPace founded?
NeuroPace was founded in 1997.
Where is NeuroPace’s headquarters located?
NeuroPace’s headquarters is located in Neuilly-sur-Seine, 92, FR.
When was NeuroPace’s last funding round?
NeuroPace’s most recent funding round was for $9.3M (USD) in June 2021.
How many employees does NeuroPace have?
NeuroPace has 167 employees as of Feb 6, 2024.
How much has NeuroPace raised to-date?
As of July 05, 2023, NeuroPace has raised a total of $307.3M (USD) since Jun 30, 2021.
Add Comparison
Total Raised to Date
$307.3M
USD
Last Update Jun 30, 2021
Last Deal Details
$9.3M
USD
Jun 30, 2021
Grant
Total Employees Over Time
167
As of Feb 2024
NeuroPace Address
Neuilly-sur-Seine,
Hauts-de-Seine
92200
France
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts